Expertise in NGS-based LDTs and Related Diagnostics
Octyne Inc has extensive experience in diagnostic and genetic test commercialization. We’ve launched more than 300 diagnostic tests as LDTs in the the clinical diagnostic space using next generation sequencing (NGS) technologies.
We consult across the development process, from assay design to commercialization + branding of single gene & multi-gene panels, exome and genomes in various disease categories that include, oncology, prenatal, neonatal, neurology, cardiac and general genetics. All processes have been set in CLIA an CAP accredited environments.